Company Overview and News
Nickel market news: "Nickel's 'electric premium' crushed by trade tensions. Mining.com reported: "Quadruple-positive whammy for nickel demand."
TNTMF PANRF GLCNF AVQ MUM CZI AMSLF POS AUZ HIG RNX PLM.RT FQVLF WNARF FQM MSMGD AXNNF MSMGF MBL PSDNF POM NMTLF SMMYY PLM CLQ HLPCF WM CSSQF LNZCF ARV XTM WSCRF
Australian Mines Limited’s (ASX:AUZ) (FRA:MJH) (OTCMKTS:AMSLF) research and development (R&D) work aimed at developing a scandium oxide process flowsheet has seen it receive an R&D tax rebate from the Commonwealth Government.
2018-09-24 seekingalpha - 1
Cobalt spot prices were slightly down in September but appear to have stabilized just below US$30/lb.
SIE PIO CLA PANRF CCZ PAN HAV MCR KBGCF CTM AXE ECSIF IGO VIC AOU HIG PCRCF PLM.RT SNNAF FQM MCRZF BXTMF MLX PSDNF POM AYR JRV SHERF CDU RGARF CHK MCRZY FTMDF KAT RER CSSQF GMRSF CZN PGM GBLEF NZRIF AZS GLCNF DLE MALRY HBNRF MEI PIONF BPLNF GAL CZI AMSLF HMI MIN POS AUZ RNX GME FQVLF AQR PTNUF WCTXD FT HNLMF ORR CDNMD 3993 UMICY CDNMF IIDDY AEOMF USCFF FTSSF KATFF BBBMF MLXEF OZMLF PLM CNJ AZRMF HLPCF BPL BHP OZL MALRF ARV
Australian Mines Ltd (ASX:AUZ) (FRA:MJH) (OTCMKTS: AMSLF) subsidiary Norwest Minerals Limited has issued a prospectus for its intended initial public offering (IPO).
Australian Mines Limited (ASX:AUZ) has had Argonaut Securities initiate research coverage with a resulting ‘spec buy’ recommendation placed on the battery metals explorer and developer.
AUZ CLQ MLM BAR AMSLF MLMZF
Australian Mines Ltd (ASX:AUZ) exploration manager Stuart Peterson updates Proactive Investors on development of the company's flagship Sconi Cobalt-Nickel-Scandium Project in northern Queensland.
Australian Mines Ltd (ASX:AUZ) has received positive, near-surface results from its extension drilling program at the Sconi Cobalt-Nickel-Scandium Project in northern Queensland.
TORONTO, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Melior Resources Inc. (TSXV: “MLR”) (“Melior” or the “Company”) is pleased to announce that it entered into a binding arrangement agreement (the “Arrangement Agreement”) with Australian Stock Exchange (“ASX”) listed Metallica Minerals Limited (ASX:“MLM”) (“Metallica”) on September 12, 2018 which sets out the terms and conditions of a merger (the “Merger”) of the two companies.
AUZ CCJMF MALRY MLM CCJMD MALRF MLR AMSLF MIN MLMZF
Australian Mines has made an agreement with a New York-based company for $12 million in funding that will be put towards completing the acquisition of the Flemington project in New South Wales.
AUZ JRV AMSLF
Australian Mines Limited (ASX:AUZ) has boosted its financial position through a $12 million investment agreement with a New York-based fund managed by Bergen Asset Management, LLC.
Nickel market news: Nickel demand in the batteries market is starting to be noticeable. As per Mining News, "electric vehicle demand will double nickel price as soon as 2022."
TNTMF GLCNF AVQ IGO MUM S2R CZI AMSLF POS AUZ HIG RNX PLM.RT REN WNARF MSMGD AXNNF MSMGF WSA RNSGF PSDNF POM AAL IIDDY NMTLF CLQ PLM AAUKF HLPCF WM CSSQF LNZCF NGLOY ARV XTM WSCRF
Cobalt miner news - BHP seeking to add cobalt sulphate from Nickel West operation. China Molybdenum net profit set to surge between 271.21% and 295.16%.
SIE PIO CLA PANRF BLT CCZ PAN HAV MCR KBGCF CTM AXE ECSIF IGO VIC BAR AOU HIG PCRCF PLM.RT SNNAF FQM MCRZF BXTMF MLX PSDNF POM AYR CDU RGARF CHK MCRZY FTMDF KAT RER BBL CSSQF BHPLF GMRSF CZN PGM GBLEF NZRIF AZS GLCNF DLE HBNRF MEI PIONF GAL CZI AMSLF BPLNF HMI POS AUZ RNX GME FQVLF AQR PTNUF FT BHPBF HNLMF ORR CDNMD 3993 UMICY CDNMF IIDDY AEOMF USCFF FTSSF KATFF BBBMF MLXEF OZMLF PLM BHP CNJ AZRMF HLPCF BPL BHP OZL ARV
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...